2 news items
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
BIAF
15 May 24
was primarily due to an increase in compensation costs and benefits from the addition of new clinical development personnel
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
BIAF
1 Apr 24
, compared with $1.4 million in 2022. The increase was primarily attributable to an increase in compensation costs and benefits as we added research
- Prev
- 1
- Next